| | Business Summary | | Tanox,
Inc.
identifies
and
develops
therapeutic
monoclonal
antibodies
to
address
significant
unmet
medical
needs
in
the
areas
of
asthma,
allergy,
autoimmune,
inflammation
and
other
related
diseases.
Tanox's
products
are
genetically
engineered
antibodies
that
target
a
specific
substance,
or
antigen.
Xolair
(trade
name
for
Omalizumab),
the
Company's
most
advanced
product
in
development,
is
a
humanized
monoclonal
antibody
that
block
IgE.
Its
therapeutic
effect
has
been
validated
through
clinical
trials
in
patients
suffering
from
allergic
asthma
and
seasonal
allergic
rhinitis.
The
Company
is
developing
Xolair
in
collaboration
with
Novartis
Pharma
AG
and
Genentech
Inc.
The
Company
has
three
products
in
clinical
development
and
anticipates
commencing
clinical
studies
of
two
additional
antibodies
late
in
2001
or
early
2002.
The
Company
is
also
evaluating
several
product
candidates
in
preclinical
and
research
studies. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Tanox,
Inc.
identifies
and
develops
therapeutic
monoclonal
antibodies
to
address
significant
unmet
medical
needs
in
the
areas
of
immunology,
infectious
diseases
and
cancer.
For
the
six
months
ended
6/30/01,
revenues
fell
98%
to
$284
thousand.
Net
loss
totaled
$11.3
million
vs.
an
income
of
$2.5
million.
Results
reflect
the
absence
of
$12
million
in
milestone
revenues
earned
under
collaborative
agreements
with
Novartis
and
Genentech
and
a
$3.9
million
restructuring
charge. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Nancy Chang, Ph.D., 51
Chairman,
Pres, CEO | $522K | $2.5M | Michael Kelly, 44
CFO,
VP | -- | -- | Katie-Pat Bowman, 46
VP,
Gen. Counsel, Sec. | -- | -- | Gary Glandon
VP
of HR | -- | -- | Matthew Moyle, Ph.D., 40
VP,
Research | -- | -- | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/t/tnox.gif)